|Articles|March 8, 2017

Tufts CSDD Releases Results of New Impact Report

A recently completed study reported that the 505(b)(2) approval pathway for new drug applications in the US has not led to shorter approval times.

A recently completed study conducted by Tufts CSDD reported that the 505(b)(2) approval pathway for new drug applications in the US, aimed at avoiding the duplication of studies performed on a previously approved drugs, has not led to shorter approval times.

Read the full release here

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!